Catalyst
Slingshot members are tracking this event:
PDUFA Date of March 2nd for BMY's Supplemental Biologics License Application (sBLA) for Opdivo in Patients With Locally Advanced Unresectable or Metastatic Urothelial Carcinoma After Platinum-Based Chemotherapy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 02, 2017
Occurred Source:
http://news.bms.com/press-release/bladdercancer/bristol-myers-squibb-receives-fda-approval-opdivo-nivolumab-previously-t
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pdufa Date, Supplemental Biologics License Application, Sbla, Locally Advanced, Unresectable, Metastatic, Urothelial Carcinoma, Platinum-based Chemotherapy, Fda
